Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Debbie, Hinnen"'
Publikováno v:
Journal of the American Association of Nurse Practitioners. 34:418-440
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::987f5929b46f2d9e587094a1a1f27a57
https://doi.org/10.1097/jxx.0000000000000661
https://doi.org/10.1097/jxx.0000000000000661
Publikováno v:
Postgraduate medicine.
People with type 2 diabetes (T2D) have a higher risk of cardiovascular (CV) disease (CVD) than those without. This increased risk begins with pre-diabetes, potentially 7-10 years before T2D is diagnosed. Selecting medication for patients with T2D sho
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c91ca229c582da3d31751630f64bd00b
https://pubmed.ncbi.nlm.nih.gov/36154802
https://pubmed.ncbi.nlm.nih.gov/36154802
Publikováno v:
Journal of the American Association of Nurse Practitioners. 34(2)
Cardiovascular disease (CVD) is a major cause of death and disability among people with type 2 diabetes (T2D), presenting a significant impact on longevity, patient quality of life, and health care costs. In the United States, attainment of recommend
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::1e84a1834288496faa4dba91fd47249a
https://pubmed.ncbi.nlm.nih.gov/35120085
https://pubmed.ncbi.nlm.nih.gov/35120085
Autor:
Debbie Hinnen, Medha Munshi, Luigi F. Meneghini, Mathieu Coudert, John Anderson, Pierre Evenou, Jasvinder Gill
Publikováno v:
Journal of diabetes and its complications. 35(4)
To better understand outcomes in people with type 2 diabetes at high risk of hypoglycemia, we conducted post hoc analyses in subgroups of participants from the real-world ACHIEVE Control study (NCT02451137) with ≥1 hypoglycemia risk factor.Insulin-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d331bc66419ac9ed3188e300b7259e5a
https://pubmed.ncbi.nlm.nih.gov/33509703
https://pubmed.ncbi.nlm.nih.gov/33509703
Autor:
Debbie Hinnen, Jodi Strong
Publikováno v:
Diabetes Spectrum : A Publication of the American Diabetes Association
Background. Patients with type 2 diabetes require treatment intensification to maintain glycemic control. Clinician reluctance, patient injection fears, hypoglycemia, weight gain, or other objections may lead to clinical inertia, whereby therapy is n
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1dd2a056d3686ac5923334161f12115c
https://doi.org/10.2337/ds17-0014
https://doi.org/10.2337/ds17-0014
Publikováno v:
Clinical Diabetes : A Publication of the American Diabetes Association
IN BRIEF Titratable fixed-ratio combinations (FRCs) of a basal insulin and a glucagon-like peptide-1 (GLP-1) receptor agonist are new therapeutic options for people with type 2 diabetes. Two FRCs—insulin degludec/liraglutide and insulin glargine/li
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::903ec92b0b95e0ef6f9a5e7749f4c14a
https://doi.org/10.2337/cd17-0048
https://doi.org/10.2337/cd17-0048
Publikováno v:
Clinical Diabetes : A Publication of the American Diabetes Association
IN BRIEF As more patents on biological medicines expire, increased numbers of biologic copies, referred to as “biosimilars,” will likely become available in the United States in the coming years. With greater availability and the drive for health
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f5030e429c1c2e6c6be58b2781c3ae77
https://doi.org/10.2337/cd16-0072
https://doi.org/10.2337/cd16-0072
Autor:
Debbie Hinnen
Publikováno v:
Clinical Diabetes : A Publication of the American Diabetes Association
In Brief For patients with type 2 diabetes who require add-on therapy to metformin plus basal insulin, GLP-1 receptor agonists may be a favorable option because they effectively manage postprandial glucose, reduce body weight, and have an overall fav
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::004db95b2cee4523c14cf64204fb14c9
https://doi.org/10.2337/diaclin.33.4.175
https://doi.org/10.2337/diaclin.33.4.175
Publikováno v:
Journal of the American Academy of Nurse Practitioners. 25:65-76
Purpose Type 2 diabetes mellitus (T2DM) is a complex metabolic disorder that affects almost 24 million Americans. Healthcare providers often do not initiate and/or intensify therapy appropriately during patient visits, which may be due, in part, to a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b813e4a646b5cfdf613a300fcd3e93ac
https://doi.org/10.1111/j.1745-7599.2012.00736.x
https://doi.org/10.1111/j.1745-7599.2012.00736.x
Publikováno v:
Current medical research and opinion. 32(9)
Hypoglycemia is an abnormally low plasma glucose concentration that may expose individuals to potential harm. It is associated with treatment of type 1 diabetes and type 2 diabetes. Diabetes-related hypoglycemia may result in various complications, r
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5721abcbf148930a858a734345ce735c
https://pubmed.ncbi.nlm.nih.gov/27142345
https://pubmed.ncbi.nlm.nih.gov/27142345